Search
Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigational[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: BALVERSA 3 MG FİLM KAPLI TABLET, 56 ADET, BALVERSA 3 MG FİLM KAPLI TABLET, 84 ADETTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalRamucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. … Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing
Categories: Vascular Endothelial Growth Factor Receptor 2 AntagonistProducts: CYRAMZA®, CYRAMZA 100MG/10 ML INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇEREN FLAKON, 1 ADETLisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL). … [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.
Categories: CD19-Directed Genetically Modified Autologous T-cell ImmunotherapiesCiltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development … [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]
Synonyms: Autologous bi-epitope BCMA-targeted CAR T-cellsAcute Non-Lymphocytic Leukemia
go.drugbank.com/conditions/DBCOND0038781Drugs: TioguanineSynonyms: Acute myeloid leukemia, no ICD-O subtype (morphologic abnormality)Cutaneous Melanoma
go.drugbank.com/conditions/DBCOND0040978Drugs: IpilimumabSynonyms: Malignant melanoma, no ICD-O subtypeSARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
go.drugbank.com/drugs/DB18705Approved[L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market.
Synonyms: SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)Ibalizumab
go.drugbank.com/drugs/DB12698ApprovedInvestigationalThis drug was approved in March 2018 for the management of treatment-resistant HIV [L1554]. … It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies [L1558, L1554].
Categories: HIV 1 Post-attachment Fusion Inhibitors, Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor